About Us|Applications|Technologies|Products|Resource Center|Service & Support|News & Events
Lateral Flow BioSensor BioChips Flow Through Dry Chemistry Solid Transferring Immunoblots Packaging qPCR FISH
Liquid Dispensing Solid Transfer Cutting Slitting In Line Lamination
Lateral Flow Batch Processing In Line Processing BioSensor Solid Transfer Handheld Automated BioChip Flow Through Immunoblot
Application Notes BioLinks Company Brochures Patents Product Data Sheets Product Videos Published Papers Technical Posters
Press Releases Events
Home > News Eventss > 14 Sep 2005: For Immediate Release

Berlin, Germany, July 18, 2006

Scienion Closes Financing Round of more than 4.5 Million Euro and Expands to Dortmund

Scienion AG has closed a financing round totaling more than 4.5 million Euro. The cash inflow enables the development of new technologies and thus the further expansion of the company. In order to develop these new technologies Scienion will establish a second development and production site in Dortmund and will move into new facilities in the BioMedizinZentrum Dortmund.

The investment was led by the new investors NRW.BANK and S-Venture Capital Dortmund GmbH and current VC investor Peppermint. Financial Partners. The VC Fonds Berlin of IBB Beteiligungsgesellschaft and ERP Start Fonds of Kreditanstalt für Wiederaufbau (KfW) participated in this round together with other existing Scienion investors. Dr. Holger Eickhoff, CEO of Scienion, explains: "We will use the new capital for developing innovative technologies in the field of low level liquid handling and its various applications as we face growing needs in this market. The BioMedizinZentrum Dortmund offers attractive conditions for our expansion and that's why we build up a second development and production site here."

"We invest in Scienion because of its convincing business plan, and we are glad to get this innovative company to Nordrhein-Westfalen," says Ernst Gerlach, CEO of NRW.BANK. Dr. Joachim Rautter of Peppermint. Financial Partners adds: "Since our investment in 2001 we have accompanied Scienion's successful development and with this new round we want to accelerate this positive development. Scienion has products and plans with a high market potential in the life science sector and that is the reason why we further invest in the company."

In its first financing round in 2001, Scienion raised start financing of approximately 6 million Euro. From the beginning of operations, Scienion has generated revenues with its innovative products and services that continually show high rates of growth.

About SCIENION AG

SCIENION AG is a life science company well positioned in the markets of ultra low volume liquid handling systems and microarray technologies. We provide our customers with an integrated product portfolio facilitating and improving multiparallel bioanalytics, high throughput screening and high throughput production of microarrays in the genomics and proteomics fields – from early research to manufacturing. Our approach is to provide our customers in pharmaceutical, biotech, diagnostic and reagents companies as well as in academic research institutions with high quality products serving as cost- and time-saving tools for their applications.

Based on Scienion’s expertise and proprietary platform technologies our product portfolio comprises hardware, consumables and services.

Scienion’s leading product is the sciFLEXARRAYER dispensing system, available in a product line of three size versions S3, S5 and S11. The piezo-electrically driven dispenser allows the aspiration of ultra low liquid volumes from different reservoirs and non-contact micro drop delivery in the picoliter to microliter range onto a variety of carriers. Presently Scienion is developing innovative integrated storage and dispensing devices. sciSWIFTs are based on Scienion’s proprietary Sterile Washfree Identifyable Fluid Technology. Disposable storage and dispensing nozzles eliminate the risk of contamination and as aspire and wash steps are no longer necessary, the spotting process is greatly accelerated.

Founded in 2000 in Berlin as a spin-off of the Max-Planck-Institute for Molecular Genetics, the company today operates from two sites, Dortmund and Berlin.

Contact:

BioDot, Inc.
Barbara McIntosh, VP Sales & Marketing
Irvine, CA 92612
Tel. +1-949-440 3685
Faxl. +1-949-440 3694
Email:  barbara.mcintosh@biodot.com
www.biodot.com

SCIENION AG
Dr. Holger Eickhoff, CEO, Press contact
Volmerstr. 7b Almut Gebhard
12489 Berlin
Tel. + 49 (0)30 - 6120 1081
Tel.: +49 (0)30 - 6392 1700
E-mail:  almut.gebhard@gmx.de
Fax: +49 (0)30 - 6392 1701
E-mail:  eickhoff@scienion.de
www.scienion.de